Is Oveporexton legal in Australia?

An oral orexin receptor 2 agonist, not a peptide, approved by the FDA on 5 August 2026 for narcolepsy type 1 in adults. In two 12 week phase 3 trials totalling 273 people it lengthened time awake on the Maintenance of Wakefulness Test by 14 to 20 minutes against roughly no change on placebo; a majority of treated participants developed insomnia and urinary frequency.

51 daltons, not a peptide. It is on this site because it is the first approved drug that acts at the receptor for orexin-A, the wake-promoting peptide whose neurons are lost in narcolepsy type 1.

Mechanism: In people with narcolepsy type 1 the hypothalamic neurons that make orexin-A and orexin-B are lost, so both orexin peptides are deficient while their receptors remain. Oveporexton is a selective agonist at orexin receptor 2 (OX2R), the receptor most tied to maintaining wakefulness, and it restores signalling at that receptor without replacing the peptide.

Regulatory history: FDA approved 5 August 2026 (Orzeyful, NDA 220860, orphan designation, priority review) for narcolepsy type 1 in adults. Controlled substance schedule pending DEA review at the time of labelling.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Oveporexton at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.